UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources06.22.21
by Tori Erxleben Rush, PharmD
Addressing the New Polypharmacy Display Measures
Blog Post
Polypharmacy is a familiar topic for many when discussing adherence and prescribing behavior. With the addition of three polypharmacy-related display measures for the 2022 CMS quality measure performance year, we turned to Tori Erxleben Rush, PharmD, RxAnte Product Director, to learn more about the display measures and their significance to health plans and their members .
06.03.21
Case Study: Improving pharmacy quality measures in a DSNP contract
Whitepaper
See how one health plan client and RxAnte took steps to leverage their existing quality program and adopt new strategies within their DSNP population to scale outreach efforts and target a greater percentage of their high-value membership.
05.28.21
Expanding the Scope of Adherence Interventions with Value of Future Adherence™
Blog Post
When considering the value of medication adherence, we have typically spoken of improving this aspect of healthcare quality in the context of CMS Stars adherence measures; however, research has also illustrated savings in total cost of care through improved medication adherence. Discover how RxAnte's Value of Future Adherence software is providing plans another way to view their members' medication use.